Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Billemont

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Targeted Oncology|May 8, 2009
Renal toxicity of targeted therapiesRonan J Kelly, Bertrand Billemont, Olivier Rixe
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 31, 2007
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertensionHassane Izzedine, Olivier Rixe, Bertrand Billemont, et al.
Investigational New Drugs|July 13, 2010
Reactivation of tuberculosis during temsirolimus therapyRomain Coriat, Olivier Mir, Stanislas Ropert, et al.
BMC Cancer|June 11, 2014
Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?Mélanie Deberne, Stanislas Ropert, Bertrand Billemont, et al.
Bulletin Du Cancer|September 13, 2007
[Angiogenesis and renal cell carcinoma]Bertrand Billemont, Jean-Baptiste Méric, Hassan Izzedine, et al.
Investigational New Drugs|January 9, 2014
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancerAudrey Bellesoeur, Edith Carton, Olivier Mir, et al.
Investigational New Drugs|September 30, 2010
Treatment of bevacizumab-induced hypertension by amlodipineOlivier Mir, Romain Coriat, Stanislas Ropert, et al.
Expert Opinion on Drug Safety|January 19, 2010
Toxicity of sorafenib: clinical and molecular aspectsBenoit Blanchet, Bertrand Billemont, Stéphane Barete, et al.
Investigational New Drugs|June 5, 2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinibRomain Coriat, Stanislas Ropert, Olivier Mir, et al.
Investigational New Drugs|August 14, 2010
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinomaCharline Gomo, Romain Coriat, Lionel Faivre, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Targeted Oncology|May 8, 2009
Renal toxicity of targeted therapiesRonan J Kelly, Bertrand Billemont, Olivier Rixe
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 31, 2007
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertensionHassane Izzedine, Olivier Rixe, Bertrand Billemont, et al.
Investigational New Drugs|July 13, 2010
Reactivation of tuberculosis during temsirolimus therapyRomain Coriat, Olivier Mir, Stanislas Ropert, et al.
BMC Cancer|June 11, 2014
Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?Mélanie Deberne, Stanislas Ropert, Bertrand Billemont, et al.
Bulletin Du Cancer|September 13, 2007
[Angiogenesis and renal cell carcinoma]Bertrand Billemont, Jean-Baptiste Méric, Hassan Izzedine, et al.
Investigational New Drugs|January 9, 2014
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancerAudrey Bellesoeur, Edith Carton, Olivier Mir, et al.
Investigational New Drugs|September 30, 2010
Treatment of bevacizumab-induced hypertension by amlodipineOlivier Mir, Romain Coriat, Stanislas Ropert, et al.
Expert Opinion on Drug Safety|January 19, 2010
Toxicity of sorafenib: clinical and molecular aspectsBenoit Blanchet, Bertrand Billemont, Stéphane Barete, et al.
Investigational New Drugs|June 5, 2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinibRomain Coriat, Stanislas Ropert, Olivier Mir, et al.
Investigational New Drugs|August 14, 2010
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinomaCharline Gomo, Romain Coriat, Lionel Faivre, et al.
Pageof 2